BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27618366)

  • 1. Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion.
    Kwegyir-Afful AK; Bruno RD; Purushottamachar P; Murigi FN; Njar VC
    FEBS J; 2016 Nov; 283(21):3898-3918. PubMed ID: 27618366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
    Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
    FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
    Kwegyir-Afful AK; Ramalingam S; Purushottamachar P; Ramamurthy VP; Njar VC
    Oncotarget; 2015 Sep; 6(29):27440-60. PubMed ID: 26196320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice.
    Kwegyir-Afful AK; Murigi FN; Purushottamachar P; Ramamurthy VP; Martin MS; Njar VCO
    Oncotarget; 2017 Aug; 8(32):52381-52402. PubMed ID: 28881737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin.
    Xu Y; Liao S; Wang L; Wang Y; Wei W; Su K; Tu Y; Zhu S
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):85-93. PubMed ID: 33159561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice.
    Mbatia HW; Ramalingam S; Ramamurthy VP; Martin MS; Kwegyir-Afful AK; Njar VC
    J Med Chem; 2015 Feb; 58(4):1900-14. PubMed ID: 25634130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
    Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
    Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models.
    Thomas E; Thankan RS; Purushottamachar P; Huang W; Kane MA; Zhang Y; Ambulos NP; Weber DJ; Njar VCO
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.
    Kwegyir-Afful AK; Ramalingam S; Ramamurthy VP; Purushottamachar P; Murigi FN; Vasaitis TS; Huang W; Kane MA; Zhang Y; Ambulos N; Tiwari S; Srivastava P; Nnane IP; Hussain A; Qiu Y; Weber DJ; Njar VCO
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma.
    Seidel P; Sun Q; Costa L; Lardinois D; Tamm M; Roth M
    Cell Signal; 2016 Oct; 28(10):1555-62. PubMed ID: 27418099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding.
    Beggs JE; Tian S; Jones GG; Xie J; Iadevaia V; Jenei V; Thomas G; Proud CG
    Biochem J; 2015 Apr; 467(1):63-76. PubMed ID: 25588502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
    Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
    Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
    Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
    Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
    Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.
    Xie J; Shen K; Jones AT; Yang J; Tee AR; Shen MH; Yu M; Irani S; Wong D; Merrett JE; Lenchine RV; De Poi S; Jensen KB; Trim PJ; Snel MF; Kamei M; Martin SK; Fitter S; Tian S; Wang X; Butler LM; Zannettino ACW; Proud CG
    Cell Mol Life Sci; 2021 Jan; 78(1):249-270. PubMed ID: 32170339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.